Navigation Links
Frost & Sullivan: Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
Date:7/24/2013

MOUNTAIN VIEW, Calif., July 24, 2013 /PRNewswire/ -- Molecular farming is poised to address the huge demand for fully functional protein therapeutics and low-cost vaccines. This plant production technology is deployable for applications in basic life sciences research, veterinary applications, personal care, and healthcare to meet the clinical needs of chronic and orphan diseases unmet by the current supply.

New analysis from Frost & Sullivan's (http://www.technicalinsights.frost.com) Emerging Trends in Molecular Farming research finds plants are preferred production systems owing to their potential to produce a wide range of recombinant molecules. Post-translational modifications in plants allow for their use in the production of complex proteins, giving them an edge over conventional bacterial systems.

For more information on this research, please email Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

"Plant farming offers a cost-effective platform for recombinant protein production, especially as setting up a plant-based platform requires low costs and provides flexibility," said a Technical Insights analyst. "These benefits prompted research on novel plant-based platforms, process design and optimization, and will lead to the development of sustainable and scalable production systems."

However, stringent regulations, possible safety issues and the lack of participation from stakeholders pose a challenge to technology development and adoption. Recombinant proteins' post-translational modifications and minor glycosylation differences from human proteins may lead to a loss in functions or immune reactions, and can reduce drug perfor
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
3. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
4. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
5. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
6. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
7. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
8. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
9. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
10. Electronic Medical Records Progress from an Enterprise-Centric Solution to a Customer-Specific Application, Finds Frost & Sullivan
11. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 Research ... of the "Inhaled Drug Delivery (London, UK - ... This Inhaled Drug Delivery meeting will cover industry ... and much more. The Co-Chairmen are Dr Steven ... , Senior Director, Mylan. Companies participating ...
(Date:9/2/2015)... , Sept. 2, 2015  Seeger Weiss LLP ... bellwether trial will commence October 13, 2015. ... the 510K fast-track approval program, Zimmer NexGen knee implant ... only requires that companies provide evidence that the product ... in order to gain permissions. In ...
(Date:9/2/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the Baird 2015 ... . The live presentation takes place on ... presentation will be webcast and may be accessed on ... Listeners are encouraged to visit the website approximately ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
... First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) -, PRINCETON, ... ) today announced that the U.S. Food and Drug,Administration (FDA) ... patients six years and older with moderately to,severely active polyarticular ...
... Model Created Using Piecewise Smooth Subdivision Surface Provides Both ... of Fallot Patients, SEATTLE, April 8, 2008 ... and volumetric insights,that help cardiologists diagnose and treat patients ... in the American Journal,Cardiology (2008; Vol. 101, Issue 1, ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3
(Date:9/3/2015)... ... 03, 2015 , ... As a result of the Patient ... health insurance plans, more employers are moving to a self-funded model for pharmacy ... 2014 United Benefit Advisors (UBA) Health Plan Survey. , UBA’s survey, the nation’s ...
(Date:9/3/2015)... ... September 03, 2015 , ... ProScrub is a set of automated tools ... repeat, and custom speed effects without the use of keyframes. Utilize ProScrub's powerful ... ProScrub tools are perfect complements to energetic video productions. ProScrub is a ...
(Date:9/3/2015)... ... 2015 , ... Mum n Me is pleased to announce the launch of ... that gives maximum protection from sun exposure, wind, bugs, and germs. The Mum n ... assurance by keeping the cover securely in place. The new car seat cover is ...
(Date:9/3/2015)... ... ... cases of prostate cancer are reported each year, along with 27,540 deaths attributed to the ... While only one man in 10,000 will typically get prostate cancer under age 40, the ... American Cancer Society. , Prostate cancer is the second leading cause of ...
(Date:9/3/2015)... ... 2015 , ... The partnership will leverage Fidson’s strong and ... to promote LodonalTM in Nigeria. The distribution will become effective, upon completion of ... the product. , Managing Director, Fidson Healthcare Plc, Dr Fidelis Ayebae, expressed that ...
Breaking Medicine News(10 mins):Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:Mum n Me Announces New Baby Car Seat Cover 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4
... , , Gail McG ... Climate , , WASHINGTON, July 13 ... featured speaker at a National Press Club Luncheon on Tuesday, July 21, 2009. ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , ...
... MINNEAPOLIS, July 13 Nonin Medical, Inc., ... clearance for its Model 7600 Regional Oximetry System. Introduced in ... in Milan, Italy, the innovative Model 7600 offers real-time monitoring ... , , Utilizing next-generation near-infrared ...
... WASHINGTON, July 13 The Health Coalition on Liability ... legislative proposals for medical liability reform that they will push ... consideration by Congress. , , ... system in order to provide fair and timely compensation to ...
... 17-year-olds without prescription, company says , MONDAY, July 13 (HealthDay ... contraceptive has been approved by the U.S. Food and Drug ... , The new Plan B One-Step will be available at ... The FDA also said it expanded over-the-counter access to Plan ...
... still transmit virus, but disease odds fall by 30 percent, ... who use condoms regularly can reduce their risk of getting ... The herpes simplex virus 2 (HSV-2) causes genital herpes, which ... that regular condom use reduces the spread of HIV and ...
... Leading hearing system ... their work on Hear the World, a global initiative to raise awareness about the importance ... ... the International Stevie Award for Communications Team of the Year for their work on Hear ...
Cached Medicine News:Health News:American Red Cross President to Address National Press Club Luncheon 2Health News:Nonin Medical Announces FDA Clearance for its Next-Generation Regional Oximetry System 2Health News:Health Coalition Sends Legislative Proposals for Medical Liability Reform to Congress 2Health News:Condoms May Reduce Herpes Risk 2Health News:Condoms May Reduce Herpes Risk 3Health News:Phonak and Hear the World Wins International Stevie Award in Sixth Annual International Business Awards 2Health News:Phonak and Hear the World Wins International Stevie Award in Sixth Annual International Business Awards 3
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
IV Prep Swab Sticks are effective, easy to apply, dries quickly and reduces bacterial contaminations. They are ideal for preparation of the skin prior to a ventipuncture or injection....
... Plus Sterile Isopropyl Alcohol ... primarily used as a ... administering injections. They are ... AAMI/ANSI/ISO 11137 standards to ...
... Aplicare's Saturated Swabsticks ... open, single-use foil-laminated pouches. ... is saturated with precisely ... solution. Each package is ...
Medicine Products: